Kemin Industries has launched ENTEROSURE™ to control the growth of pathogenic bacteria in poultry and livestock.
The company unveiled its latest intestinal health product at a global launch event in Dubai, the United Arab Emirates. Its newest probiotic solution promotes a healthy microbiome, drives intestinal resilience, manages gut health challenges and improves animal productivity.
Enteric disease challenges are an ever-present pressure on livestock and poultry producers, who are already facing significant performance and economic impact from the global trend toward reduced antimicrobial use and the rising cost of raw materials. These challenges require an effective and comprehensive solution that helps drive intestinal resilience to prevent disease before it develops—all while safeguarding animal health, welfare, growth and performance.
"Leveraging the pioneering research that launched CLOSTAT™, our novel solution addresses the changing needs of animal producers," said GS Ramesh, worldwide group president (Animal Nutrition and Health) at Kemin Industries. "ENTEROSURE, through its proprietary blend of probiotic Bacillus strains, expands on the scientifically proven efficacy of CLOSTAT's Bacillus subtilis PB6 against Clostridium perfringens by also managing the growth of Escherichia coli and other Enterobacteriaceae, such as salmonella."
Intestinal resilience is a crucial factor in producers' hierarchy of needs for their animals; up to 80% of antimicrobial use is intended to achieve resilience in the gastrointestinal system, a vital component in animal production. Kemin continues to drive innovation through its probiotic research programme to support intestinal health management.
The company undertook a multiyear, global project to discover advanced solutions to enhance intestinal resilience while maintaining a robust programme to improve feed conversion and weight gain and combat pathogens that contribute to dysbiosis, diarrhea, wet litter issues, foot-pad lesions and mortality.
Visit Kemin at: www.kemin.com